- March 27, 2024
- Posted by: jaymanpandya
- Category: Uncategorized
- Heads (Health Data Specialists) is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in oncology studies.
- Veeda Clinical Research, together with its subsidiary Bioneeds, offers a comprehensive portfolio of clinical, preclinical and bio-analytical services to support innovator, biosimilar and
generic drug development programs of global clients. - Heads gain access to the Indian and South-East Asian markets, offering access of patient population to its clients.
- Veeda expands its reach to major geographies and adds capabilities of late-stage clinical trial execution with strong focus on Oncology
Dublin (Ireland)/Ahmedabad (India), March 20, 2024:
Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately
held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe,
North America and Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to
clinical development extending to post commercial launch.
The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets. India’s diverse
demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special
diseases.
With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia
Pacific. Veeda’s ever-growing relationship with large biopharma companies and access to KOL’s across multiple countries will accelerate execution of global clinical trials in both the western and
eastern populations. In recent years, Veeda has added expertise in the late stage clinical and global trials for large molecules. High quality and efficient clinical trial execution remains the top
priority for the clients of the combined entity.
Sharing details related to common synergies between Veeda and Heads, Dr. Mahesh Bhalgat, Group – CEO of Veeda Clinical Research, said, “With the growing emphasis on global clinical
trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards
driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies.”
Elaborating on the prospects of this partnership, Mr. Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, “As we integrate the operations of both the companies, this is an
exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us
to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide.”
“There is a very strong cultural fit between Heads and Veeda,” said Dr. George Kouvatseas, Partner, Heads. “Both companies share a dedication to scientific leadership, expansion of highly
specialized services to meet the emerging needs of our clients, an uncompromising focus on quality, and a belief that our strength is in our people and the way in which they work together.
During the integration phase, Heads will continue to offer uninterrupted support to client programs. The Veeda and Heads organization together are committed to nimble operations
through a structured integration process without impact to ongoing client programs.”
About Veeda Clinical Research Limited:
Veeda Clinical Research Limited (“Veeda”) is one of the largest independent, full-service clinical research organizations, headquartered in Ahmedabad, India. Veeda offers a range of
bioequivalence studies and early and late phase clinical trials. Veeda has successfully completed several regulatory inspections and is approved by USFDA, UK MHRA, ANVISA (Brazil), and WHO.
Veeda has experience in conducting complex clinical studies. Visit https://www.veedacr.com/
About Heads:
Heads is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in haemato-oncology studies. It provides complete range of clinical
trial services, from start-up to completion, from Phase I to IV. In addition, it offers strategic oncology drug development consulting and expert advice, as the team understands the
challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market. Visit https://heads-research.com/